Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
09/2010
09/14/2010CA2482989C Sugar-free hard coatings prepared from liquid maltitol comprising dp4+ fraction
09/14/2010CA2466996C Non-gelatinous capsule shell compositions and capsules using the same
09/14/2010CA2464151C Ribavirin syrup formulations
09/14/2010CA2451327C Osmotic implant with membrane and membrane retention means
09/14/2010CA2444739C Water-soluble container having at least two openings
09/14/2010CA2443623C A jasmonate pharmaceutical composition for treatment of cancer
09/14/2010CA2432009C Pharmaceutical preparations comprising a salt of an antibiotic and an antiphlogistic and use thereof
09/14/2010CA2408949C Medical dressing assembly and associated method of using the same
09/14/2010CA2386231C Membrane translocating peptide drug delivery system
09/14/2010CA2347913C Oral administration of adenosine analogs
09/14/2010CA2295140C Stable insulin formulations
09/14/2010CA2290696C Immunopotentiating composition
09/14/2010CA2261666C Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin
09/10/2010WO2010102252A1 Oral dosage forms having a high loading of a gabapentin prodrug
09/10/2010WO2010102245A1 Solid dispersion comprising resveratrol
09/10/2010WO2010102196A2 Controlled-release ophthalmic vehicles
09/10/2010WO2010102192A2 Non-steroidal anti-inflammatory ophthalmic compositions
09/10/2010WO2010102148A2 An improved dry powder drug delivery system
09/10/2010WO2010102078A1 Enhanced bimatoprost ophthalmic solution
09/10/2010WO2010102071A1 Sustained release oral dosage forms of an r-baclofen prodrug
09/10/2010WO2010102066A1 Dextran polymer powder for inhalation administration of pharmaceuticals
09/10/2010WO2010102065A1 Pharmaceutical compositions of dextran polymer derivatives
09/10/2010WO2010102041A2 Composition and method for control of diabetes
09/10/2010WO2010102020A1 Insulin formulations for rapid uptake
09/10/2010WO2010101989A1 PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
09/10/2010WO2010101758A1 Peri-corneal drug delivery device
09/10/2010WO2010101694A1 Dynamic bio-nanoparticle elements
09/10/2010WO2010101588A1 Organic chewable supplement
09/10/2010WO2010101555A1 A process for forming stabilized ophthalmic solutions
09/10/2010WO2010101474A1 Soft edged pad
09/10/2010WO2010101472A1 Pad with fluid barrier
09/10/2010WO2010101237A1 Polypeptides and antibacterial or antiseptic use of same
09/10/2010WO2010101226A1 Nucleic acid complex and nucleic acid-delivering composition
09/10/2010WO2010101178A1 Amino acid-conjugated cyanoacrylate polymer particles
09/10/2010WO2010101115A1 Package of solid pharmaceutical preparation
09/10/2010WO2010100657A2 A novel oral controlled release dosage forms for water soluble drugs
09/10/2010WO2010100656A2 Storage stable prostaglandin product
09/10/2010WO2010100564A2 Injectable biomaterial
09/10/2010WO2010100514A2 Pharmaceutical composition containing a fermented, dehydrated material with amorphous crystalline structure
09/10/2010WO2010100506A2 Delivery system
09/10/2010WO2010100414A1 Abuse resistant formulation
09/10/2010WO2010100252A1 Method of dissolving antifungal agent, and compositions with a high concentration of antifungal agent, suitable for application to the nail
09/10/2010WO2010100219A2 Pharmaceutical composition containing 1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-, (1r)-, methanesulfonate
09/10/2010WO2010100218A1 Cationic oil-in-water emulsions containing prostaglandins and uses thereof
09/10/2010WO2010100217A1 Anionic oil-in-water emulsions containing prostaglandins and uses thereof
09/10/2010WO2010100207A1 Pharmaceutical compositions of active pharmaceutical ingredient comprising sulphonylurea moiety with excellent dissolution properties
09/10/2010WO2010100200A2 Lyophilised antibody formulation
09/10/2010WO2010100197A1 Resveratrol compositions for use as dietary supplements
09/10/2010WO2010100179A2 Self-forming gel system for sustained drug delivery
09/10/2010WO2010081781A4 Energetic nutritional composition comprising a laxative, electrolytes and carbohydrates
09/10/2010WO2010079506A3 Pharmaceutical composition of aripiprazole
09/10/2010WO2010076812A4 Topical herbal formulation for treatment of acne and skin disorders
09/10/2010WO2010070141A3 Microparticles comprising adipose stem cells
09/10/2010WO2010066815A3 Encapsulating system for cest imaging with chelate q greater than or equal to 2
09/10/2010WO2010062996A3 Ribavirin composition
09/10/2010WO2010062147A3 Crystal form of adefovir dipivoxil, preparation method thereof, and pharmaceutical composition containing the same
09/10/2010WO2010057188A3 Fast-acting, dietary supplement containing compositions and methods of producing the compositions
09/10/2010WO2010054083A3 Inhalation formulation for treating and prophylatic use in bacteria, mycobacterial and fungal respiratory infections
09/10/2010WO2010053337A3 Slow-release particle and a production method therefor
09/10/2010WO2010053335A3 Method for producing powder containing nanoparticles of insoluble drug, powder produced thereby and pharmaceutical composition containing same
09/10/2010WO2010041279A4 Sustained release drug delivery system
09/10/2010WO2010041015A3 Chewable gelled emulsions
09/10/2010WO2010009451A3 Methods for enhancing the stability of polyorthoesters and their formulations
09/10/2010WO2009150228A3 Hydroxypropyl cellulose capsule shell
09/10/2010WO2009131704A3 Nanostructures suitable for sequestering cholesterol
09/10/2010WO2009130225A3 Self-microemulsifying systems incorporated into liquid core microcapsules
09/10/2010WO2009117316A3 Pharmaceutical compositions having desirable bioavailability
09/10/2010WO2009106997A3 Amorphous arformoterol l-(+)-tartrate
09/10/2010WO2009104205A8 Delayed release formulation of chloride channel activator
09/10/2010WO2009089422A3 Inhalation drug products, systems and uses
09/10/2010WO2009070609A3 Therapeutic targeting of il-6 using sirna in neutral liposomes
09/10/2010CA2792241A1 Delivery system
09/10/2010CA2754558A1 Organic chewable supplement
09/10/2010CA2754251A1 Insulin formulations for rapid uptake
09/10/2010CA2754200A1 Injectable biomaterial
09/10/2010CA2754157A1 Cationic oil-in-water emulsions containing prostaglandins and uses thereof
09/10/2010CA2754156A1 Anionic oil-in-water emulsions containing prostaglandins and uses thereof
09/10/2010CA2754089A1 Pharmaceutical composition containing 1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-, (1r)-, methanesulfonate
09/10/2010CA2753947A1 Non-steroidal anti-inflammatory ophthalmic compositions
09/10/2010CA2753860A1 Oral dosage forms having a high loading of a gabapentin prodrug
09/10/2010CA2753703A1 Nucleic acid complex and nucleic acid-delivering composition
09/10/2010CA2753664A1 Abuse resistant formulation
09/10/2010CA2753638A1 Method of dissolving antifungal agent, and compositions with a high concentration of antifungal agent, suitable for application to the nail
09/10/2010CA2753057A1 Sustained release oral dosage forms of an r-baclofen prodrug
09/10/2010CA2749352A1 Storage stable prostaglandin product
09/09/2010US20100227937 Antimicrobial adhesive system
09/09/2010US20100227933 Pharmaceutical composition formulated for pre-gastric absorption of monoamine oxidase b inhibitors
09/09/2010US20100227929 Transdermal compositions
09/09/2010US20100227896 Use of vitamin pp compounds
09/09/2010US20100227008 Salicylic acid acne spray formulations and methods for treating acne with same
09/09/2010US20100226997 Controlled-release ophthalmic vehicles
09/09/2010US20100226996 Compositions and methods of delivery of pharmacological agents
09/09/2010US20100226995 Microencapsulated bioactive agents for oral delivery and methods of use thereof
09/09/2010US20100226994 Granule, tablet and methods for producing the same
09/09/2010US20100226993 Composition for regenerative treatment of cartilage disease
09/09/2010US20100226992 Pharmaceutical Composition for Delivery of Receptor Tyrosine Kinase Inhibiting (RTKi) Compounds to the Eye
09/09/2010US20100226991 Solid inorganic/organic hybrid with modified surface
09/09/2010US20100226990 Method of Producing Porous Microparticles
09/09/2010US20100226989 Nanoparticulate megestrol formulations
09/09/2010US20100226988 Cross-linking of low-molecular weight and high-molecular weight polysaccharides, preparation of injectable monophase hydrogels, polysaccharides and hydrogels obtained
1 ... 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 ... 2991